Comparing specific and empirical treatments for eosinophilia
Comparison of Outcome Between Specific Anthelminthic Treatment According to Test Results and Empirical Anthelminthic Treatment in Eosinophilic Patient
This study is testing whether specific treatments for high eosinophil counts work better than general treatments when doctors aren't sure about a parasitic infection.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 700 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Prince of Songkla University Academic / other |
| Locations | 1 site (Hat Yai, Changwat Songkhla) |
| Trial ID | NCT06265870 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of specific versus empirical anthelminthic treatments in patients with eosinophilia, a condition characterized by elevated eosinophil counts. Participants will undergo various parasite detection methods, including stool microscopy, stool culture, and PCR, to improve the accuracy of diagnosing parasitic infections. The study aims to determine whether empirical treatment can be justified in cases where stool tests are inconclusive or unavailable. By comparing treatment outcomes, the research seeks to provide clearer guidelines for managing eosinophilia in clinical practice.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with an absolute eosinophil count greater than 500 cells per microliter and a white blood cell count less than 10,000 cells per microliter.
Not a fit: Patients with urgent medical conditions, active infections, or those who have received anthelminthic drugs within the last six months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective and targeted treatments for patients suffering from eosinophilia caused by parasitic infections.
How similar studies have performed: While some studies have shown the efficacy of empirical treatment approaches, this study aims to provide a more structured comparison, making it a novel contribution to the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants who come for check-ups at general practitioner, primary care unit, and Srivejchavat Premium Center have an absolute eosinophil count greater than 500 cells/microliter with a white blood cell count less than 10,000 cells/microliter. * Age at least 18 years old * Consent to participate in research Exclusion Criteria: * Having any characteristics that need urgent care 1.1 Having history of unintended significant weight loss is defined as the loss of body weight exceeding 10% within a span of six months without deliberate attention. 1.2 Physical examination revealed a body temperature equal to or greater than 37.8 degrees Celsius, lymphadenopathy or hepatosplenomegaly. 1.3 CBC revealed blast cell * Receiving anthelminthic drug within 6 months * Underlying cancer (active stage), HIV, HBV, HCV, collagen vascular disease, active TB * Allergy to albendazole, ivermectin, or metronidazole * Pregnancy or lactation * Serum transaminase higher than 2 times of upper normal limit * Taking medications that may induce eosinophilia within the past three months, such as herbal supplements, NSAIDs, Salicylic acid, Carbamazepine, Colchicine, Nitrofurantoin, Dapsone, or Minocycline, was reported.
Where this trial is running
Hat Yai, Changwat Songkhla
- Prince of Songkla University - Hat Yai Campus: Prince of Songkla University — Hat Yai, Changwat Songkhla, Thailand (Recruiting)
Study contacts
- Principal investigator: Thareerat Ananchaisarp — Prince of Songkla University - Hat Yai Campus: Prince of Songkla University
- Study coordinator: Thareerat Ananchaisarp
- Email: thareerat.a@psu.ac.th
- Phone: 66858898592
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.